Prostate cancer (PCa) is the most common malignant tumor in males, accounting for almost 1 in 5 new cancer diagnoses in the USA. 1 Despite recent reductions in age-standardized mortality, PCa remains the third most common cause of cancer-related mortality in males. 1,2 Standard curative treatment for prostate-confined disease includes radical prostatectomy and radiotherapy. 3 According to 2017 American Urological Association guidelines, whole-gland cryoablation (CA) is a third intention alternative curative therapy for patients unsuitable for standard treatments with good life expectancy (>10 years) and intermediate-risk disease (i.e. prostate specific antigen (PSA) 10.0-20.0 ng ml −1 , Gleason score = 7, cT2b-c); and may be offered to low-risk patients (PSA <10.0 ng ml −1 , Gleason Score <7, cT1c-T2a) following discussion of potential complications and absence of survival benefit compared with active surveillance. 4 CA has also been proposed as salvage therapy for patients with local recurrence following radical radiotherapy. 5 Several studies have established that whole-gland and focal CA for primary/radio-recurrent PCa provides acceptable